Faruqi and Faruqui, LLP Logo
Share this page

PixarBio Corporation (PXRB)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In PixarBio Corporation To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in PixarBio Corporation (“PixarBio” or the “Company”) (OTC:PXRB) of the March 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased PixarBio securities pursuant to the Company’s private placement that closed on October 30, 2016 (the “Private Placement”); and/or publicly traded on the open market between October 31, 2016 and January 20, 2017 (the “Class Period”).  The case, ALLEN v. PIXARBIO CORPORATION f/k/a BMP HOLDINGS INC. et al, No. 2:17-cv-00496 was filed on January 25, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees; and PixarBio’s’ current and prospective development efforts lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.

Specifically, on January 23, 2017, the Securities and Exchange Commission (“SEC”) announced the temporary suspension of trading in the securities of PixarBio stating, in part, that “the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1.”

Given the SEC’s suspension of PixarBio securities, shares of PixarBio are illiquid, thus causing damage to investors.

Take Action

If you invested in PixarBio securities pursuant to the Company’s Private Placement and/or during the aforementioned Class Period and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding PixarBio’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    PixarBio Corporation (PXRB)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 01/26/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.